国外药品上市许可持有人委托开展药物警戒监管对我国的启示

doi:10.19803/j.1672-8629.2020.11.05

摘要/Abstract

摘要： 目的基于《中华人民共和国药品管理法》和《药品生产监督管理办法》关于药品上市许可持有人开展药物警戒的制度要求,探讨我国药品上市许可持有人委托开展药物警戒模式及其管理方式。方法研究美国、欧洲、英国等药品监管机构关于药品上市许可持有人委托开展药物警戒的规章制度,对比我国的法律法规,结合我国《药物警戒委托协议撰写指导原则》,对药物警戒委托活动的开展提出建议。结果与结论 明确药品上市许可持有人和受托方的责任与义务是进行药物警戒委托的基础,药品上市许可持有人应对受托方药物警戒工作进行考核评估,药品监管机构的药物警戒检查工作应涵盖受托方的检查,应侧重检查法规执行和药物安全性数据的管理。

关键词: 药物警戒, 委托, 管理, 药品上市许可持有人

Abstract: Objective To explore modes and management methods of pharmacovigilance subcontracted by marketing authorization holders in China based on system requirements for marketing authorization holders stipulated by the Drug Administration Law and the Measures for the Supervision over and Administration of Pharmaceutical Production. Methods The laws and regulations enacted by drug regulatory authorities concerning pharmacovigilance subcontracted by marketing authorization holders in the United States, Europe, and the United Kingdom were studied and compared with those of China. Combined with the guidelines for pharmacovigilance entrustment agreements in China, opinions or suggestions on the development of pharmacovigilance commission activities were presented. Results & Conclusion To clarify the responsibilities and obligations of the holder and the trustee is the basis of pharmacovigilance commission. Holders should evaluate pharmacovigilance practices of trustees. Pharmacovigilance inspection by drug regulatory agencies should cover the inspection of trustees and focus on the inspection of compliance and management of drug safety data.

Key words: pharmacovigilance, commission, administration, marketing authorization holder

中图分类号:

R951

刘丽丽. 国外药品上市许可持有人委托开展药物警戒监管对我国的启示[J]. 中国药物警戒, 2020, 17(11): 773-776.

LIU Lili. Pharmacovigilance Subcontracted by Foreign Marketing Authorization Holders[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 773-776.

参考文献

[1] Yuan Lin. Zhang Gaolong. Sun Qiang.The beginning and end of China's accession to ICH and its sSignificance[J]. China Food Drug Administration(中国食品药品监管), 2012, 12(9):4-13.
[2] NMPA.Comprehensively implementing the "Four strictest measures" to effectively ensure public drug safety, the newly revised Drug Administration Law was deliberated and passed [EB/OL]. (2019-08-26)[2019-12-01]. http://www.nmpa.gov.cn/WS04/CL2056/357685.html.
[3] NMPA. Regulation for the administration of drug registration [EB//OL] (2020-01-22) [2020-04-10] http://www.nmpa.gov.cn/WS04/CL2077/376150.html.
[4] Guidelines on good pharmacovigilance practices[EB/OL]. (2012-05-10)[2019-11-05]. https://www.ema.europa.eu/en/documents/other/guidelines-good-pharmacovigilance-practices-introductory-cover-note-public-consultation-first-seven_en.pdf.
[5] Wu zhiang, Bi Kaishun. Cause analysis of risk in drug risk management-about natural risk of drugs[J]. Chinese Pprescription Ddrugs(中国处方药), 2008,15(1): 49-51
[6] WHO.Research on challenges and opportunities for pharmacov-igilance in low-and middle-income countries EB/OL]. (2019-07-27)[2019-12-01]. https://www.who.int/tdr/grants/calls/pharmac-ovigilance/en/
[7] EMA. Guideline on good pharmacovigilance practices (GVP) Module I-Pharmacovigilance systems and their quality systems [EB/OL]. (2012-06-22)[2019-12-04]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacov-igilance-practices-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf.
[8] EMA. Guideline on good pharmacovigilance practices (GVP) Module II-Pharmacovigilance system master file (Rev 2) [EB/OL]. (2017-03-28)[2019-12-05]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev-2_en.pdf.
[9] EMA. Guideline on good pharmacovigilance practices (GVP) Module IV-Pharmacovigilance audits (Rev 1) [EB/OL]. (2015-08-03) [2019-12-05]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-iv-pharmacovigilance-audits-rev-1_en.pdf.
[10] EMA. Guideline on good pharmacovigilance practices (GVP) Module V-Risk management systems (Rev 2) [EB/OL]. (2017-03-28)[2019-12-05]. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices.
[11] Wang Tao, Wang Dan, Dong duo. Analysis of the US pharmacov-igilance system and iIts eEnlightenment to China[J]. Herald of Medicine(医药导报), 2017,36(4): 361-365.
[12] FDA. Postmarketing Drug Safety and Inspection Readiness[EB/OL]. (2018-06-19)[2020-04-10]. https://www.fda.gov/media/113986/download.
[13] MHRA. Guidance Good pharmacovigilance practice (GPvP) [EB/OL]. (2019-10-09)[2019-12-05]. https://www.gov.uk/guidance/good-pharmacovigilance-practice-gpvp.
[14] Sang yuan, Wu Shifu, Lu Changfei. Problems and Thoughts on ADR reporting and monitoring in manufacturing enterprises from the perspective of inspection[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(4):215-218.
[15] Clement JP MD.Outsourcing PV: Core Competencies[J]. Pharma R&D Today, 2016,18(6):34.
[16] Notice of Shanghai Pudong New Area Biological Industry Association on issuing "guidelines for Shanghai pharmacovigilance commission agreement"[EB/OL]. (2018-11-26)[2019-11-30]. https://www.spbia.cn/Article/201811/201811260001.shtml?from=groupmessage.
[17] Dong duo, Wu Guizhi, Wang Dan, et al. Brief introduction and eEnlightenment of pharmacovigilance in UK[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2014,11(8):478-481.
[18] MHRA.Service Provider inspections[EB/OL]. (2019-10-09) [2020-4-21]. https://www.gov.uk/guidance/good-pharmacovi-gilance-practice-gpvp.